Q-omics provides the consensus-scored CDC20 profile across patient tissues and cancer cell-line models. CDC20 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CDC20 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CDC20 RNA expression shows 25,603 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where CDC20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC20 survival associations across molecular data types. CDC20 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC20 RNA expression–survival associations across cancer types. High CDC20 expression shows unfavorable associations in ACC, MESO, KIRP, KIRC, LIHC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CDC20 RNA expression.
This table summarizes CDC20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CDC20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC20 shows higher tumor expression in HNSC, LUAD, BLCA, KIRP, KIRC and COAD. The HNSC box plot shows higher CDC20 RNA expression in tumor versus normal tissue (log2 FC = +2.502, t-test p < 0.001).
This table shows molecular features associated with CDC20 in patient tissues and cancer cell lines. In patient samples, CDC20 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
